Objective To review the current understanding of the underlying molecular, biologic, and genetic mechanisms involved in ovarian cancer development and how these mechanisms can be targets for prevention, detection, and treatment of the disease and its recurrence.
Methods In May 2012, we convened a meeting of researchers, clinicians, and consumer advocates to review the state of current knowledge on molecular mechanisms and identify fruitful areas for further investigations.
Results The meeting consisted of 7 scientific sessions ranging from Epidemiology, Early Detection, and Biology to Therapeutics and Quality of Life. Sessions consisted of talks and panel discussions by international leaders in ovarian cancer research. A special career development session by the Congressionally Directed Medical Research Program Department of Defense Ovarian Cancer Academy as well as an oral abstract and poster session showcased promising new research by junior scientists.
Conclusions Technological advances in the last decade have increased our knowledge of the molecular mechanisms involved in a host of biological activities related to ovarian cancer. Understanding the role these mechanisms play in cancer initiation and progression will help lead to the development of prevention and treatment modalities that can be personalized to each patient, thereby helping to overcome this highly fatal malignancy.
- Ovarian neoplasms
- Cancer stem cells
- Micro RNA
- Nuclear receptors
- Individualized medicine
- Cancer vaccines
- Quality of life
- Patient reportable outcomes
- Clinical trials
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Support for the Ovarian Cancer Symposium was provided by National Cancer Institute Division of Cancer Prevention (R13-1165638). Grant support was provided by educational grants from Abbot and Genetech. Additional support was provided by Magee-Womens Hospital, the National Ovarian Cancer Coalition, Dr and Mrs Joseph L Kelley, the Fabrizio Family, the Morris and Carolyn Barkon Lectureship in Gynecologic Oncology Survivorship, and the Jewish Healthcare Foundation.
The authors declare no conflicts of interest.